pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
CYTOKINETICS · news · pharmadog
← back to CYTOKINETICS
News mentioning CYTOKINETICS
31
stories
19d
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
Aug 31, 26
ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
biopharma dive
Aug 31, 26
A winner, a loser, and a mid-stage signal from a major cardiology research conference
stat
Aug 31, 26
STAT+: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapy
stat
Aug 31, 26
STAT+: After a rough stretch, mRNA gets a boost — at least for now
stat
Aug 30, 26
STAT+: FDA approves Protagonist and Takeda’s drug for rare blood cancer
stat
Aug 30, 26
STAT+: Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua
stat
Aug 28, 26
STAT+: AstraZeneca and Ionis detail surprise failure of heart disease drug, with Alnylam closely watching
stat
Aug 28, 26
STAT+: Cytokinetics details trial win for what could be its next approval
stat
Aug 28, 26
#ESC26: Data in hand, Cytokinetics looks to expanded Myqorzo approval
endpoints
Aug 24, 26
News on AstraZeneca, Cytokinetics, Novartis — what to look out for at ESC 2026
endpoints
Aug 14, 26
Cytokinetics brings patent suit against Bristol Myers, escalating rivalry
endpoints
Aug 14, 26
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
Aug 6, 26
Braveheart pumps more life into biotech IPO market with $382M expected debut
biospace
Aug 6, 26
Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui
fiercebiotech
Jul 30, 26
Attovia, Braveheart and Vogenx seek more than $500M across trio of IPOs
fiercebiotech
Jul 30, 26
Recon: FDA adcomm votes against Capricor’s DMD drug; Cytokinetics gets UK approval, NICE backing for heart drug
raps
Jul 16, 26
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno
biospace
Jul 15, 26
Braveheart, Attovia join next wave of biotech IPOs
biopharma dive
Jul 15, 26
Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rival
endpoints
Jun 29, 26
10 clinical trials to watch in the second half of 2026
biopharma dive
Jun 16, 26
Edgewise heart drug passes key trial test
biopharma dive
May 14, 26
Create Medicines raises $122M to bolster in vivo CAR-T therapies
biopharma dive
May 11, 26
Braveheart Bio's Hengrui-licensed cardiac drug scores second clinical win
endpoints
May 7, 26
Seaport’s IPO adventure, obesity pill battles, and Makary’s troubles
stat
May 7, 26
STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
stat
May 6, 26
STAT+: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price
stat
May 5, 26
STAT+: Are analysts too quick to gloss over Lilly’s liver case?
stat
May 5, 26
Cytokinetics heart drug scores in closely watched trial
biopharma dive
May 5, 26
Cytokinetics succeeds where Bristol Myers failed in heart muscle disease
endpoints
← prev
page 1 of 2
next →
